Is Your Patient Eligible?

Oncotype DX GPS patient - Lloyd

Your patients with clinically localized prostate cancer might be candidates for the Oncotype DX Genomic Prostate Score (GPS) test.

The Oncotype DX Genomic Prostate Score assay is intended for patients who have:

icon Biopsy within 3 years

icon Not started treatment

icon Localized prostate cancer*

* Excludes NCCN® very-high risk prostate cancer

Eligibility

Patients with National Comprehensive Cancer Network® (NCCN®) very low-, low, intermediate-, and high-risk disease are eligible.
VIEW NCCN RISK STRATIFICATION CHART

NCCN Guidelines Chart

Insurance and financial assistance

The Oncotype DX GPS test is covered by Medicare (for NCCN very low-, low-, intermediate-, and high-risk prostate cancer). Private insurance coverage varies. To help patients navigate insurance and other payment options for Oncotype DX testing, Exact Sciences offers the Genomic Access Program (GAP) and detailed information about financial assistance. Email Customer Service or call us 866-ONCOTYPE (866-662-6897).


African-American Data in Clinical Studies

Learn more about how the Oncotype DX GPS test can help make more informed treatment decisions in racially diverse populations.


REFERENCES

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V2.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 1, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product.

Making cancer care smarter.®